Skip to main content
Medical information Clinical review pending

Genetic Testing

FLVCR1 Gene Ataxia Posterior Column with Retinitis Pigmentosa Genetic Test

Genetic test using Next Generation Sequencing (NGS) to identify mutations in the FLVCR1 gene associated with ataxia and retinitis pigmentosa. Helps diagnose and understand neurological conditions.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
A blood sample is required for this test. Confirm specific volume and collection tube type with the laboratory before booking.
Results
Confirm turnaround time with the laboratory before booking.
Preparation
No special preparation is typically required for a blood draw. However, confirm with the laboratory if any specific instructions apply.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the FLVCR1 Gene Ataxia Posterior Column with Retinitis Pigmentosa Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Unexplained balance problems or coordination difficulties (ataxia)
  • ✓Progressive vision loss, especially night blindness (retinitis pigmentosa)
  • ✓Family history of ataxia or retinitis pigmentosa
  • ✓Neurological symptoms suggestive of FLVCR1-related disorders
  • ✓Genetic counseling for individuals with relevant symptoms
  • ✓Confirmation of suspected diagnosis based on clinical presentation
02

In plain language

What this test helps you understand

This test helps identify specific genetic mutations in the FLVCR1 gene that are known to cause or contribute to Ataxia Posterior Column with Retinitis Pigmentosa. Identifying these mutations can confirm a diagnosis, aid in understanding the underlying cause of symptoms, and inform management strategies.
The FLVCR1 Gene Ataxia Posterior Column with Retinitis Pigmentosa NGS Genetic DNA Test is an advanced diagnostic tool using Next Generation Sequencing (NGS) technology. It identifies genetic mutations linked to neurological disorders, specifically those involving ataxia (balance and coordination issues) and retinitis pigmentosa (a type of vision loss). This test is designed for individuals experiencing symptoms suggestive of these conditions, providing valuable insights into their genetic health and potential management strategies.

This test specifically analyzes the FLVCR1 gene. Variations in this gene can affect the function of neurons and retinal cells, potentially leading to the development of neurological conditions. By examining the patient's genetic material, healthcare providers can determine if specific mutations associated with ataxia and retinitis pigmentosa are present.

Understanding the results can aid in diagnosis, prognosis, and guiding treatment decisions. It also provides information for genetic counseling and family planning.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationNo special preparation is typically required for a blood draw. However, confirm with the laboratory if any specific instructions apply.
SampleA blood sample is required for this test. Confirm specific volume and collection tube type with the laboratory before booking.
MethodologyNext Generation Sequencing (NGS) is used to analyze the FLVCR1 gene for specific mutations.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test analyzes the FLVCR1 gene specifically. It may not detect mutations in other genes that can cause similar symptoms. A negative result does not completely rule out a genetic cause for the symptoms. The test may not identify all possible variants within the FLVCR1 gene. Interpretation of variants of uncertain significance can be complex.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Symptoms typically include progressive ataxia (problems with balance and coordination) and retinitis pigmentosa (progressive vision loss, often starting with night blindness).
This test is specifically for identifying mutations in the FLVCR1 gene. It is most appropriate for individuals whose symptoms and family history suggest a potential FLVCR1-related disorder, as determined by a healthcare professional.
Your doctor or a genetic counselor will discuss the results with you, explaining what they mean for your health and potential management options.
This test identifies current genetic mutations. While it can provide information about potential risks, it does not definitively predict all future health outcomes.
Insurance coverage varies. Please check with your insurance provider regarding coverage for genetic testing.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp